Department of Clinical Nutrition and Speech-Language Therapy, Clinic of Clinical Services, St. Olavs Hospital - Trondheim University Hospital, Trondheim, Norway.
Faculty of Medicine and Health Sciences, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
PLoS One. 2021 Mar 8;16(3):e0248247. doi: 10.1371/journal.pone.0248247. eCollection 2021.
The objective of the study was to assess associations of the rs9939609 FTO allele to glucose tolerance, hepatic and total insulin sensitivity (IS) in individuals with obesity. From a low-dose hyperinsulinemic euglycemic clamp with glucose-tracer, hepatic IS was assessed by rates of basal and suppressed glucose appearance (Ra), a measure of endogenous glucose production (EGP), and the hepatic insulin resistance index (HIR). Total IS was assessed by rates of glucose infusion (GIR), disappearance (Rd), and metabolic clearance (MCR). From a meal test we assessed IS by the Matsuda index and glucose tolerance by glucose and insulin measurements in the fasted state and postprandially for 2.5 h. The meal test was performed in 97 healthy individuals with BMI ≥35 in similar-sized risk-allele groups (n = 32 T/T, 31 A/T, and 34 A/A), and 79 of them performed the clamp. We analyzed outcomes separately for males and females, and adjusted glucose Ra, Rd, MCR, GIR, and HIR for fat mass. We did not find genotype effects on EGP. Among males, genotype A/A was associated with a significantly lower glucose Rd, MCR, and Matsuda index score relative to genotype T/T. Glucose tolerance was significantly lower in males with genotype A/T vs. T/T and A/A. For females, there were no genotype effects on hepatic or total IS, or on glucose tolerance. Independently of genotypes, females displayed a significantly better hepatic and total IS, and better glucose tolerance than males. We conclude that in subjects with similar obesity we did not register any FTO risk-allele effect on hepatic IS. A FTO risk-allele effect on total IS was registered in males only, findings which need to be reproduced in further studies. Results confirm marked differences in IS between the biological sexes and extend present knowledge by demonstrating a lower endogenous glucose production in females vs. males in uniformly obese individuals.
本研究旨在评估 rs9939609 FTO 等位基因与肥胖个体葡萄糖耐量、肝胰岛素敏感性(IS)和总体 IS 的相关性。采用小剂量胰岛素强化正常血糖钳夹技术结合葡萄糖示踪剂,通过基础和抑制状态下葡萄糖出现率(Ra)评估肝 IS,Ra 是内源性葡萄糖生成(EGP)的指标,肝胰岛素抵抗指数(HIR)也通过该指标进行评估。通过葡萄糖输注率(GIR)、消失率(Rd)和代谢清除率(MCR)评估总体 IS。通过进餐试验评估 IS,用空腹和餐后 2.5 小时的血糖和胰岛素测量值评估葡萄糖耐量。在 BMI≥35 的 97 名健康个体中进行了进餐试验,按风险等位基因分组(n=32 T/T、31 A/T 和 34 A/A),其中 79 名个体进行了钳夹试验。我们分别对男性和女性进行了分析,并对脂肪量进行了 Ra、Rd、MCR、GIR 和 HIR 的调整。我们未发现基因型对 EGP 有影响。在男性中,与基因型 T/T 相比,基因型 A/A 与 Rd、MCR 和 Matsuda 指数评分显著降低相关。与 T/T 相比,A/T 基因型的男性葡萄糖耐量显著降低。在女性中,肝或总体 IS 以及葡萄糖耐量与基因型无关。无论基因型如何,女性的肝和总体 IS 以及葡萄糖耐量均显著优于男性。我们得出结论,在肥胖程度相似的人群中,我们没有发现 FTO 风险等位基因对肝 IS 有任何影响。只有在男性中,FTO 风险等位基因对总体 IS 有影响,这一发现需要在进一步的研究中得到验证。结果证实了生物性别之间 IS 存在显著差异,并通过证明在肥胖个体中女性的内源性葡萄糖生成率低于男性,扩展了现有知识。